Immune checkpoint inhibitors’ application in cancer immunotherapy

Written by Sino Biological
Cancer research Drug discovery and development Immunology

Immune checkpoint inhibitors (ICIs) represent a significant breakthrough in cancer therapy. ICIs can produce a co-stimulatory or inhibitory signal regulating antigen recognition of T-cell receptors in the process of an immune response. The continuous development of novel ICIs and the discovery of biomarkers have substantially enhanced the therapeutic efficacy of these agents.

In this Application Note, Sino Biological provides an overview of how ICIs are applied in cancer treatment.

Modified-Immune Checkpoint Inhibitors Application in Cancer Immunotherapy_compressed (1)

 

This content was provided by

Follow Sino Biological on Twitter, Facebook and on LinkedIn.

 

Submit Your Research to the F1000Research Oncology Gateway

Share your oncology research with the global scientific community through the F1000Research Oncology Gateway. With trusted publishing, open access, and transparent peer review, your work will uphold the highest standards of research integrity while driving innovation in cancer treatment and understanding.

Join a trusted platform that accelerates progress in oncology. Submit your research today at F1000Research Oncology Gateway.